Evome Medical Technologies (EVMT) Q2 2024 earnings summary

Executive summary

• Leadership executed a turnaround plan, stabilizing operations after a period of no revenue growth, rising losses, and high debt.

• Achieved $421,000 in positive adjusted EBITDA for Q2 2024, marking a return to profitability and business stabilization.

• Revenue reached $10.5 million, with core Biodex contributing $6.1 million, up 59% from Q1 2024.

• Reduced total debt by $2.7 million in Q2, including $2.6 million in acquisition debt; total debt down 18% since June 2023.

• Promoted Gordon Bean to CFO as of August 1, 2024.

Financial highlights

• Q2 2024 revenue reached $10.5 million, with $6.1 million from the core Biodex Rehab business.

• Core business revenue grew $2.3 million (59%) over Q1 2024; gross profit from core business rose $1.2 million (104%) over Q1.

• Gross profit totaled $3.3 million, with Biodex gross profit at $3.2 million, up 60% from Q1 2024.

• Positive adjusted EBITDA of $421,000 in Q2 2024, a $1.7 million improvement over Q1 and $1.4 million year-over-year.

• Net loss for Q2 2024 was $2.28 million.

Outlook and guidance

• Core Biodex business expected to generate $27.5 million in annual revenue, $10.9 million gross profit, and $2.1 million adjusted EBITDA on a run-rate basis.

• Incremental revenue growth anticipated in 2025 from new white-labeled products, with minimal marginal cost.

• Management optimistic about maintaining financial momentum into Q3 and beyond for Biodex.

• Plans to divest remaining non-core business units to retire acquisition debt and focus on Biodex.

• Continued focus on posting positive adjusted EBITDA and revenue growth in coming quarters.